It is generally agreed that sudden unexpected death in epilepsy could be averted if the patient could be rapidly ventilated following the seizure. Diaphragmatic pacing is a surgical intervention used in spinal cord injury, sleep apnea, and similar causes of ventilatory failure. In this mouse model, all of the animals receiving the intervention survived, compared with death in most of the animals in the control arm of the study.

A chart review of 81 million individuals yielded two matched groups of more than 150,000 patients each: one with COVID and the other with influenza. In these populations, the risk of seizures and epilepsy was higher in the COVID group. The HR of epilepsy after COVID compared with influenza was highest in individuals who were not hospitalized and in those under the age of 16.

A blood test focusing on a set of eight autoantibody markers was 97% effective in detecting the presence of Alzheimer’s disease-related pathology up to 10 years before onset of clinical symptoms. According to the investigators, “this is the first blood test to accurately detect Alzheimer’s-related pathology several years before either clinical symptoms or more expensive and invasive tests can identify the disease.”

Originally published in JAMA Psychiatry, a broad-based study shows nearly 7% of OUD patients are adding buprenorphine to urine sample to fake treatment adherence. Buprenorphine spiking suggests to the physician that the treatment plan is not working—especially in patients continuing illicit drug use.

Dr. Christopher Flowers, professor and chair of the Lymphoma Myeloma Department at the University of Texas MD Anderson Cancer Center, discusses the GO29365 study, which examined the combination of polatuzumab vedotin and bendamustine rituximab. The trial’s exploratory nature involved looking at the combination of polatuzumab vedotin with bendamustine and rituximab in a dose-finding component to determine the best dose to give to patients with follicular lymphoma and diffuse large B-cell lymphoma.

Because each patient reports unique challenges, there is no “one size fits all” approach to managing cancer-associated venous thrombosis (CAT). Thrombosis is a complication that HCPs are not recognizing early enough in the face of multiple options for appropriately treating and managing CAT; additionally, there is a lack of awareness of new CAT management clinical data. Although the morbidity and mortality of VTE in cancer patients remain high, unfortunately, its management is not given the same priority. And although recommendations suggest an individualized approach to managing these patients, clinical practice adoption is slow. Published guidelines and clinical trial data do not always correspond to real-world practice and prescribing practices. As a result, many existing CAT management protocols must be updated as new guidance is warranted.